Sugi Predict

Sugi Predict / Compounds / SCHEMBL10146774

SCHEMBL10146774

SCHEMBL10146774

CCOC(=O)c1cc(C)c(N)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.51
▸ CA1 P00915 3/20 0.51
▸ CA2 P00918 3/20 0.51
▸ CA7 P43166 3/20 0.51
▸ CA9 Q16790 3/20 0.51
▸ CA14 Q9ULX7 3/20 0.51
▸ LMNA P02545 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ MAOA P21397 1/20 0.50
▸ MAPT P10636 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ ESR1 P03372 4/20 0.46
▸ HSD11B1 P28845 3/20 0.45
▸ ESR2 Q92731 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6640579 0.91 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL1101657 0.88 CA12 (0.60) CA12CA1CA2CA7CA9
SCHEMBL3525726 0.84 CA1 (0.49) CA12CA1CA2CA7CA9
SCHEMBL8284687 0.83 CA12 (0.55) CA12CA1CA2CA7CA9
SCHEMBL8060962 0.83 CA12 (0.46) CA12CA1CA2CA7CA9
SCHEMBL1613283 0.83 HSD17B2 (0.54) CA12CA1CA2CA7CA9
SCHEMBL16056303 0.83 LMNA (0.52) CA12CA1CA2CA7CA9
SCHEMBL17955668 0.81 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL3595464 0.81 ESR1 (0.59) CA12CA1CA2CA7CA9
SCHEMBL5682889 0.81 HSD11B1 (0.44) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3808743-A1 HIV REPLICATION INHIBITING PYRIMIDINES Janssen Pharmaceutica NV (BE) 2021-04-21 — — EP disclosed
US-10611732-B2 HIV replication inhibiting pyrimidines JANSSEN PHARMACEUTICA NV (BE) 2020-04-07 — — US disclosed
EP-2298761-B1 HIV INHIBITING PYRIMIDINES DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2020-03-25 — — EP disclosed
US-20190322628-A1 HIV REPLICATION INHIBITING PYRIMIDINES JANSSEN PHARMACEUTICA NV (BE) 2019-10-24 — — US disclosed
US-10370340-B2 HIV replication inhibiting pyrimidines JANSSEN PHARMACEUTICA NV (BE) 2019-08-06 — — US disclosed
US-9981919-B2 HIV replication inhibiting pyrimidines JANSSEN PHARMACEUTICAL N.V. (BE) 2018-05-29 — — US disclosed
US-9981919-B2 HIV replication inhibiting pyrimidines JANSSEN PHARMACEUTICAL N.V. (BE) 2018-05-29 — — US disclosed
US-20170320835-A1 HIV REPLICATION INHIBITING PYRIMIDINES JANSSEN PHARMACEUTICA NV (BE) 2017-11-09 — — US disclosed
US-20170320835-A1 HIV REPLICATION INHIBITING PYRIMIDINES JANSSEN PHARMACEUTICA NV (BE) 2017-11-09 — — US disclosed
US-20170121292-A1 HIV REPLICATION INHIBITING PYRIMIDINES JANSSEN PHARMACEUTICA NV (BE) 2017-05-04 — — US disclosed
US-9580392-B2 HIV replication inhibiting pyrimidines JANSSEN PHARMACEUTICA NV (BE) 2017-02-28 — — US disclosed
EP-2953927-B1 SUBSTITUTED BENZAMIDES WITH ACTIVITY TOWARDS EP4 RECEPTORS DRACONIS PHARMA S L (ES) 2016-11-16 — — EP disclosed
US-20140343006-A1 HIV Replication Inhibiting Pyrimidines JANSSEN PHARMACEUTICA NV (NL) 2014-11-20 — — US disclosed
US-20140343006-A1 HIV Replication Inhibiting Pyrimidines JANSSEN PHARMACEUTICA NV (NL) 2014-11-20 — — US disclosed
EP-2765128-A1 Substituted benzamides with activity towards EP4 receptors Almirall, S.A. (ES) 2014-08-13 — — EP disclosed
US-20120076835-A1 HIV INHIBITING PYRIMIDINES DERIVATIVES GUILLEMONT JEROME EMILE GEORGES (FR) 2012-03-29 — — US disclosed
US-20120076835-A1 HIV INHIBITING PYRIMIDINES DERIVATIVES GUILLEMONT JEROME EMILE GEORGES (FR) 2012-03-29 — — US disclosed
US-8080551-B2 HIV inhibiting pyrimidines derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2011-12-20 — — US disclosed
US-8080551-B2 HIV inhibiting pyrimidines derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2011-12-20 — — US disclosed
EP-2298761-A1 HIV inhibiting pyrimidines derivatives Janssen Pharmaceutica NV (BE) 2011-03-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343006-A1 HIV Replication Inhibiting Pyrimidines RRM2B, CCNO, RRM2 CA12 4766/4885CA1 4629/4885CA2 4582/4885
US-20170121292-A1 HIV REPLICATION INHIBITING PYRIMIDINES RRM2B, CCNO, RRM2 CA12 4766/4885CA1 4629/4885CA2 4582/4885
US-20190322628-A1 HIV REPLICATION INHIBITING PYRIMIDINES RRM2B, CCNO, RRM2 CA12 4766/4885CA1 4629/4885CA2 4582/4885
US-10611732-B2 HIV replication inhibiting pyrimidines RRM2B, CCNO, RRM2 CA12 4766/4885CA1 4629/4885CA2 4582/4885
US-20120076835-A1 HIV INHIBITING PYRIMIDINES DERIVATIVES TYMS, PNP, DUT CA12 4884/4885CA1 4883/4885CA2 4801/4885
US-10370340-B2 HIV replication inhibiting pyrimidines RRM2B, CCNO, RRM2 CA12 4766/4885CA1 4629/4885CA2 4582/4885
US-20170320835-A1 HIV REPLICATION INHIBITING PYRIMIDINES RRM2B, CCNO, RRM2 CA12 4766/4885CA1 4629/4885CA2 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.